Healthcare

AstraZeneca and Oracle launch AI collaboration for clinical-trial optimization

AstraZeneca and Oracle launched an AI and real-world-data collaboration, beginning with an Abu Dhabi program to identify uncontrolled-hypertension patients and improve clinical-trial recruitment with M42.

AstraZeneca and Oracle announced a non-binding collaboration combining AstraZeneca’s clinical-development and regulatory expertise with Oracle’s real-world data, cloud infrastructure, and AI-enabled clinical capabilities. The companies will explore applications including clinical-trial recruitment, earlier diagnosis, drug-safety monitoring, and the use of real-world evidence in care workflows. The first program will be conducted in Abu Dhabi with UAE healthcare company M42 and will focus on identifying patients with uncontrolled hypertension, supporting guideline-directed care, and improving clinical-trial recruitment. The initiative matters because patient identification and recruitment remain major barriers to efficient clinical research, while integrating research insights into routine care could accelerate access to trials and evidence-based treatment. Additional work is expected across oncology, cardiovascular, renal and metabolic, respiratory, immunology, and rare-disease areas. The collaboration is intended to operate across the United States, Middle East, and Europe under applicable local regulations.

Original source: AstraZeneca

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI